Carcinogenicity of Lipid-Lowering Drugs

JAMA: The Journal of the American Medical Association

Volumn 275, Issue 19, 1996, Pages 1479-1480

  Illingworth, D Roger ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; ANTILIPEMIC AGENT; GEMFIBROZIL; MEVINOLIN; ACYL COENZYME A OXIDASE; CELL RECEPTOR; OXIDOREDUCTASE; TRANSCRIPTION FACTOR;

CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; LIVER; LIVER TUMOR; NOTE; ANIMAL; MICROBODY; RODENT;

ACYL COENZYME A; ANTILIPEMIC AGENTS; GEMFIBROZIL; HUMANS; LIVER; LIVER NEOPLASMS; LOVASTATIN; ACYL-COA OXIDASE; ANIMALS; MICROBODIES; OXIDOREDUCTASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RODENTIA; TRANSCRIPTION FACTORS;

EID: 15844393656     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1996.03530430023026     Document Type: Letter

References (5)

1. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996; 275:55-60.
2. Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia: a double-blind crossover study. JAMA. 1989;262:3154-3160.
3. Illingworth DR, Sexton GJ. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest. 1984;74:1972-1978.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.